Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
- PMID: 36244360
- DOI: 10.1016/S2215-0366(22)00317-0
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
Abstract
Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its efficacy, safety, and tolerability in depression. We searched Pubmed, Embase, and the Cochrane Library and identified three randomised controlled trials, eight open-label trials, and 30 case series and reports on maintenance ketamine treatment. We found intravenous, intranasal, oral, and possibly intramuscular and subcutaneous maintenance ketamine treatment to be effective in sustaining antidepressant effect in treatment-resistant depression. Tachyphylaxis, cognitive impairment, addiction, and serious renal and urinary problems seem uncommon. Despite the methodological limitations, we conclude that from a clinical view, maintenance ketamine treatment seems to be of therapeutic potential. We recommend both controlled and naturalistic studies with long-term follow-up and sufficient power to determine the position of maintenance ketamine treatment within routine clinical practice.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests JKEV received a speaker's fee from Janssen Pharmaceuticals, outside the submitted work. RAS received research funding for two randomised clinical trials with generic oral esketamine from the Netherlands Organisation for Health Research and Development and the National Health Care Institute, a speaker's fee and investigator initiated research grant from Janssen Pharmaceuticals, and consultancy fees from GH Research, Beckley PsyTech, and QPS, outside the submitted work. The other authors declared no competing interests.
Similar articles
-
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. Cochrane Database Syst Rev. 2021. PMID: 34510411 Free PMC article.
-
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.Cochrane Database Syst Rev. 2021 Oct 8;10(10):CD011611. doi: 10.1002/14651858.CD011611.pub3. Cochrane Database Syst Rev. 2021. PMID: 34623633 Free PMC article.
-
Antidepressants for the treatment of depression in people with cancer.Cochrane Database Syst Rev. 2018 Apr 23;4(4):CD011006. doi: 10.1002/14651858.CD011006.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Mar 31;3:CD011006. doi: 10.1002/14651858.CD011006.pub4. PMID: 29683474 Free PMC article. Updated.
-
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.J Psychiatr Res. 2021 May;137:232-241. doi: 10.1016/j.jpsychires.2021.02.058. Epub 2021 Mar 1. J Psychiatr Res. 2021. PMID: 33706168
-
WITHDRAWN: Antidepressants for depression in medical illness.Cochrane Database Syst Rev. 2007 Jul 18;2000(4):CD001312. doi: 10.1002/14651858.CD001312.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636666 Free PMC article.
Cited by
-
Neurobiological Underpinnings of Hyperarousal in Depression: A Comprehensive Review.Brain Sci. 2024 Jan 4;14(1):50. doi: 10.3390/brainsci14010050. Brain Sci. 2024. PMID: 38248265 Free PMC article. Review.
-
Psychotropic Drugs Reemerging as Headache Medicines.CNS Drugs. 2024 Sep;38(9):661-670. doi: 10.1007/s40263-024-01107-x. Epub 2024 Jul 22. CNS Drugs. 2024. PMID: 39037675
-
Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.Focus (Am Psychiatr Publ). 2025 Apr;23(2):195-205. doi: 10.1176/appi.focus.20240040. Epub 2025 Apr 15. Focus (Am Psychiatr Publ). 2025. PMID: 40235610
-
S-ketamine Alleviates Neuroinflammation and Attenuates Lipopolysaccharide-Induced Depression Via Targeting SIRT2.Adv Sci (Weinh). 2025 Jun;12(23):e2416481. doi: 10.1002/advs.202416481. Epub 2025 Apr 2. Adv Sci (Weinh). 2025. PMID: 40171943 Free PMC article.
-
Psilocybin in pharmacotherapy of obsessive-compulsive disorder.Pharmacol Rep. 2024 Oct;76(5):911-925. doi: 10.1007/s43440-024-00633-1. Epub 2024 Aug 1. Pharmacol Rep. 2024. PMID: 39088105 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical